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is important. We evaluated the role of mesothelin and osteopontin biomarkers in distinguishing
MPM from benign pleural disease. We also, evaluated whether mesothelin and osteopontin were
related to successful pleurodesis or not.
Materials and methods: Mesothelin and osteopontin were assayed in blood and pleural ﬂuid with
commercial ELISA kits in a series of 20 patients with malignant mesothelioma and 20 patients with
benign pleural effusion (10 patients with tuberculous pleural effusion and 10 patients with benign
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116 F.M. Amany et al.Results: Both mesothelin and osteopontin in blood and pleural ﬂuid showed statistically high levels
in malignant pleural mesothelioma than benign pleural effusion with a cutoff point of 3.5 nmol/L for
pleural mesothelin and 3.3 nmol/L for serum mesothelin and of 280 ng/ml for pleural osteopontin and
260 ng/ml for serum osteopontin. Also, there are statistically signiﬁcant high levels of mesothelin in
epitheliod subtype than sarcomatoid andmixedmesothelioma. Cases ofMPMwho have a cutoff value
of more than (4 nmol/L) for pleural mesothelin and (3.4 nmol/L) for serummesothelin and (370 ng/ml)
for pleural osteopontin and (350 ng/ml) for serum osteopontin had failed pleurodesis but cases that
have values less than the cutoff points had successful pleurodesis.
Conclusion: The combined assays of blood and pleural ﬂuid mesothelin and osteopontin biomark-
ers have a high diagnostic and prognostic yield in malignant pleural mesothelioma patients undergoing
pleurodesis.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Malignant pleural mesothelioma (MPM) is an aggressive tu-
mor which usually has a poor prognosis. Its incidence is
increasing throughout most of the world, and it is predicted
that it will rise in the next 10–15 years as a result of wide-
spread exposure to asbestos in the past decades [1]. The man-
agement of patients with MPM remains controversial. Due to
the usually advanced stage at presentation, the discovery of a
marker that would permit an earlier diagnosis could lead to
an increase of the proportion of patients diagnosed with
early-stage mesothelioma. To date, there is no recognized mar-
ker for the early diagnosis of mesothelioma or for screening of
at risk asbestos – exposed individuals.
Recent reports have raised the interest of soluble mesoth-
elin-related peptides and osteopontin as possible markers for
diagnosing MPM [2,3]. Osteopontin is an extracellular cell
adhesion protein involved in non mineral bone matrix forma-
tion, but is also a key cytokine in mediating type immune re-
sponses [4]. It was implicated in the regulation of metastatic
spread of tumor cells [5]. In fact, osteopontin was ﬁrst de-
scribed as being secreted by transformed malignant epithelioid
cells [6]. Mesothelin is a physiologically expressed membrane
bound peptide on the surface of normal mesothelial cells and
is also found expressed in various cancers, including malignant
mesothelioma [7], pancreatic or ovarian carcinoma, sarcomas
and in some gastrointestinal or pulmonary carcinomas [8].
A soluble form, released from the membrane bound mes-
othelin, can be detected in sera from mesothelioma patients.
The mechanism of release of mesothelin from the cell surface
into the blood is unknown. Serum mesothelin level is low in
healthy subjects exposed to asbestos [9].Aim of the work
To assess the diagnostic value of both blood and pleural ﬂuid
mesothelin and osteopontin biomarkers in the diagnosis of
malignant pleural mesothelioma and to evaluate their prognos-
tic value in the success of pleurodesis in those patients.Patients and methods
The study included 40 patients with pleural effusion suspected
of having mesothelioma. Patients were selected from Chest,Internal Medicine and Cardiothoracic Surgery departments,
Zagazig University Hospitals from June 2009 to June 2012.
All patients had clinical symptoms suggestive of a diagnosis
of MPM (i.e. at least chest pain and dyspnea), associated with
pleural thickening, or pleural nodules and pleural effusion on
the thoracic computed tomography scan [10].
Exclusion criteria
 Previous therapy against malignant mesotheliom.
 Other malignant pleural effusion.
Samples taken from patients
1. Blood samples for
 Mesothelin and osteopontin assays.
2. Pleural ﬂuid samples for
 Biochemistry: proteins g/L and glucose g/L and LDH.
 Total and differential cells count of pleural effusion.
 Cytology for malignant cells.
 Mesothelin and osteopontin assays.
3. Final diagnosis based on tissue pleural biopsy by thoraco-
scopic biopsy or through limited thoracotomy in difﬁcult
cases for thoracoscopic biopsy or by CT guided pleural
biopsy in difﬁcult cases for surgery. Histopathological
examination was done for all patients.
So, patients were divided after histopathological diagnosis
into (20) cases proved to have MPM and (20) cases who had
benign pleural effusion (benign asbestos pleural effusion 10
cases, and 10 patients with tuberculoses pleural effusion).
The malignant mesothelioma cases were subclassiﬁed into
(14) cases with epithelioid type, (4) cases with sarcomatoid
type and (2) cases with mixed type after histopathological
examination.
Pleurodesis was done by cardiothoracic surgeons for cases
proved to be malignant mesothelioma by talc slurry pleurode-
sis. Premedication and sedation in the form of benzodiazepine
should be appropriate that is, maintenance of verbal communi-
cation and cooperation. Sedation employed before pleurodesis
should be conducted with continuous monitoring with pulse
oximetry and in a setting where resuscitation equipment is
available. Lignocaine (3 mg/kg; maximum 250 mg) should be
administered intrapleurally just prior to sclerosant administra-
Mesothelin and Osteopontin as Diagnostic and Prognostic Markers of Malignant Pleural Mesothelioma 117tion [11]. Six grams of sterile talc were instilled, as a slurry, in
200-ml saline solution, through a large syringe. The talc slurry
was injected in the chest drain inserted after thoracoscope or
primary inserted for pleurodesis. The tube is clamped and the
syringe connected to the drain. The slurry is injected and the
drain re-clamped. Then the patients were placed in a series of
positions by the nursing staff one side ﬁrst, then the other, with
the head up followed by head down – each position for about
10 min. This distributes the talc slurry over the surface of vis-
ceral and parietal pleurae. After an hour the drain will be
unclamped to allow excess talc and saline to drain out. The
drain is usually removed the following day after a check
X-ray [12].
Mesothelin and osteopontin assays
Mesothelin levels were measured in both pleural ﬂuid and ser-
um samples of all patients, using the mesomark assay (Fujire-
bio Diagnostics, Malvern, PA) from serum and pleural ﬂuid
stored at 80 C.
Osteopontin levels in serum and pleural ﬂuid were
measured in duplicate using the human osteopontin enzyme
– linked immunosorbant assay kits (Immunobiological
Laboratories, Minneapolis, MN). The assays were performed
according to the manufacturer’s instructions where results
differed by more than 15%. A triplicate was performed. If at
least two results were not within 15% of each other, results
were discarded.
Statistical analysis
Data were checked, entered and analyzed by using SPSS (ver-
sion 19). Data were expressed as mean ± SD for quantitative
variables, number and percentage for categorical variables.
ANOVA (F test), t test, chi-squared or ﬁsher exact tests were
used when appropriate.
P< 0.05 was considered statistically signiﬁcant.
Results
In Table 1 we studied 40 patients suspected of having mesothe-
lioma. They were divided after histopathological examination
into 20 cases proved to have mesothelioma and 20 cases withTable 1 Demographic data of the studied patients.
Demographic data Mesothelioma
No = 20 patients
Age in years
mean ± SD 62.8 ± 9.6
Sex [n (%)]
Male 13 (65%)
Female 7 (35%)
Asbestos exposure
Yes 14 (70%)
No 2 (0%)
Likely 4 (20%)benign pleural effusion (previously asbestoses exposed 10 cases
with benign pleural effusion and 10 cases with tuberculous
asbestos pleural effusion). Male sex was predominant than fe-
male with a mean age of 62.8 ± 9.6 years in the mesothelioma
patients. Most of the mesothelioma patients had a history of
asbestos exposure (70%).
Table 2 shows that pleural ﬂuid protein, and LDH were
higher and pleural ﬂuid glucose level was lower in MPM than
in benign pleural effusion and the difference was statistically
highly signiﬁcant. Pleural ﬂuid cytology was positive for meso-
thelioma in only 40% of MPM patients. It was non conclusive
in 60% of them. Thoracoscopic pleural biopsy was conclusive
for mesothelioma in 70% of MPM patients. CT guided pleural
biopsy was diagnostic in 20% of MPM patients whereas surgi-
cal biopsy was the last resort in 10% of patients. The different
histological types in the studied MPM patients were epithelioid
in 70% of patients, sarcomatoid in 20% and mixed type in
10% of patients.
Table 3 illustrated that both serum and pleural Mesothelin
are signiﬁcantly higher in cases of mesothelioma pleural effu-
sion than in benign pleural effusion. Also, there is a cutoff va-
lue of (3.5 nmol/L) for pleural mesothelin and (3.3 nmol/L)
for serum mesothelin to differentiate between benign and
malignant pleural effusion secondary to mesothelioma. As re-
gards to pleural ﬂuid and serum osteopontin, their levels were
signiﬁcantly higher in MPM than in benign pleural effusion.
There is a cutoff value of (280 ng/ml) for pleural osteopontin
and (260 ng/ml) for serum osteopontin to differentiate be-
tween benign and malignant pleural effusion secondary to
MPM.
Table 4 shows that both serum and pleural mesothelin and
osteopontin biomarkers are statistically highly signiﬁcant in
epithelioid type than sarcomatoid and mixed types.
Table 5 shows cases of MPM that had cutoff values of
(4 nmol/L) for pleural mesothelin and (3.4 nmol/L) for serum
mesothelin. As regards osteopontin, cases had cutoff values
of pleural. Osteopontin (370 ng/ml) and of serum osteopontin
(350 ng/ml) had failed pleurodesis but cases below these cutoff
points had successful pleurodesis.
Table 6 illustrates that pleural mesothelin shows higher sen-
sitivity than speciﬁcity (95.0% compared to 90.0%). On the
opposite side, pleural osteopontin shows higher speciﬁcity than
sensitivity (95.0% compared to 90.0%) in the diagnosis of
malignant pleural mesothelioma.Benign pleural eﬀusion
No = 20 patients
P-value
60.3 ± 7.5 >0.05
12 (60%) >0.05
8 (40%) >0.05
10 (50%) >0.05
8 (40%) <0.05
2 (10%) >0.05
Table 2 Diagnostic methods used in the studied patients.
Method of diagnosis Mesothelioma
(20 patients)
Benign pleural eﬀusion
(20 patients)
P value
Pleural ﬂuid biochemistry
– Total protein g/L 54.1 (50–58.2) 48 (43–53.1) <0.001
– Glucose g/L 0.93 (0.58–1.17) 1.48 (1.12–1.14) <0.001
– LDH (IU/L) 1562 (304–1820) 554 (373–735) <0.001
Pleural ﬂuid cytology
– Positive for mesothelioma 8 (40%) 0.0 (0%) <0.05
– Negative for mesothelioma 0 (0%) 14 (70%) <0.05
– Non conclusive 12 (60%) 6 (30%) >0.05
Tissue biopsy
– Thoracoscopy 14 (70%) 12 (60%) >0.05
– Surgery 2 (10%) 2 (10%) >0.05
– CT guided pleural biopsy 4 (20%) 6 (30%) >0.05
Histopathology
– Epithelioid 14 (70%) –
– Sarcomatoid 4 (20%) –
– Mixed 2 (10%) –
Table 3 Pleural ﬂuid and serum cutoff values of mesothelin and osteopontin in malignant pleural mesothelioma and benign pleural
effusion patients.
Tumor biomarkers Malig. pl. mesothelioma
(median and range)
Benign pl. eﬀ
(median and range)
P-value
Pleural mesothelin cutoﬀ (3.5 nmol/L) 3.8 (3.3–4.3) 3.1 (2.9–3.6) <0.001
Serum mesothelin cutoﬀ (3.3 nmol/L) 3.6 (3.2–4.1) 2.8 (2.2–3.4) <0.001
Pleural osteopontin cutoﬀ (280 ng/ml) 390 (270–460) 210 (205–285) <0.001
Serum osteopontin cutoﬀ (260 ng/ml) 370 (250–440) 220 (210–270) <0.001
Table 4 Pleural ﬂuid and serum values of mesothelin and osteopontin in the different histological types of mesothelioma.
Tumor biomarkers Epithelioid sub type
No = 14
Sarcomatioid
No = 4
Mixed
No = 2
P-value
Pleural mesothelin (nmol/L) 4.2 (4.0–4.4) 3.7 (3.5–3.9) 3.9 (3.8–4.0) <0.001
Serum mesothelin (nmol/L) 4.1 (3.9–4.3) 3.6 (3.5–3.7) 3.8 (3.6–4.0) <0.001
Pleural osteopontin (ng/ml) 430 (440–420) 380 (390–370) 390 (410–370) <0.001
Serum osteopontin (ng/ml) 410 (430–390) 370 (380–360) 380 (400–360) <0.001
Table 5 The impact of pleural ﬂuid and serum values of both mesothelin and osteopontin on the success of pleurodesis.
Tumor biomarkers Failed pleurodesis (7 patients)
Median (range)
Successful pleurodesis (13 patients)
Median (range)
P
Pleural mesothelin (nmol/L) 4 (3.9–4.3) 3.2 (3.1–3.3) 0.016*
Serum mesothelin (nmol/L) 3.8 (3.5–4.1) 2.8 (2.2–2.4) 0.026*
Pleural osteopontin (ng/ml) 420 (380–480) 300 (240–390) <0.001*
Serum osteopointin (ng/ml) 360 (365–440) 295 (250–360) <0.001*
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Mesothelioma is a highly aggressive cancer, which is often
diagnosed up to 30–40 years after asbestos exposure. Because
tumor growth is generally insidious and the usual clinical signs
(dyspnea, cough and chest pain) are non-speciﬁc mesothelioma
diagnosis is generally obtained too late [13]. Thus disease
markers have been searched in an attempt to help earlydiagnosis. Recently, osteopontin and mesothelin have been
proposed as early markers for MPM diagnosis [3].
Some studies showed that osteopontin is a high sensitiv-
ity marker but with poor speciﬁcity and mesothelin had a
good speciﬁcity but with a lower sensitivity for MPM, so,
we evaluated the diagnostic and prognostic value of the
combination of the two markers in the assessment of
MPM patients.
Table 6 Validity of both mesothelin and osteopontin biomarkers in the diagnosis of malignant pleural mesothelioma.
Sensitivity Speciﬁcity PV Accuracy
+ve –ve
Pleural mesothelin 95.0 90.0 90.5 94.7 92.5
Serum mesothelin 95.0 95.0 95.0 95.0 95.0
Pleural osteopontin 90.0 95.0 94.7 90.0 92.5
Serum osteopontin 95.0 85.0 86.4 94.4 90.0
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thelioma were enrolled. They were divided according to histo-
pathological examination into 20 cases with benign pleural
effusion and 20 proved mesothelioma (MPM) patients. Male
sex was predominant than female with a mean age of
(62.8 ± 9.6) years. Male predominance is related to their occu-
pational exposure to asbestos dust more than females. This
agrees with Steven et al. [10].
Also (70%) of MPM cases had a history of asbestos expo-
sure. This agrees with Daniel and Steven [14] who reported
that asbestosis is the principal carcinogen associated with
malignant pleural mesothelioma, indeed, malignant pleural
mesothelioma was rare before the widespread use of asbestos,
also the lifetime risk of developing MPM among asbestos
workers is 8–13%. They also reported that, there is typically
a long latency period of approximately 30–40 years from the
time of asbestos exposure to the development of mesotheli-
oma. This also explains the predominance of old age among
the studied MPM patients with an average of 62.8 y.
Table 2 showed that biochemical variables of pleural ﬂuid
are good indicators of (MPM) in which glucose is markedly
decreased while LDH and protein is markedly increased.
The results mentioned previously by Silvia Bielsa et al. [15]
that pH < 7.2, glucose < 60 mg/dl and LDH> 600 l/L with
karnosfsky index <70 and massive effusion deﬁned as the one
that exceeds the hilar region can be used as predictive factors
of decreased survival in malignant mesothelioma.
Also Table 2 showed that thoracoscopic biopsy gave the
highest diagnostic yield than other biopsies (70% in MPM
and 60% in benign pleural effusion). This agrees with Murray
and Nadel’s [16] who reported that, the preferred technique
for surgical biopsy is via pleuroscopy. Not only does pleuros-
copy have the advantage of obtaining large samples, but,
also, it permits the drainage of effusions and freeing up of a
trapped lung. In addition, if the lung is not trapped, talc can
be insufﬂated at the end of the procedure to achieve pleurod-
esis. Also Carbone et al. [17] mentioned that video assisted
thoracoscopy is a useful technique among patients of
mesothelioma.
Table 3 showed that both serum and pleural mesothelin are
signiﬁcantly higher in cases of (MPM) than in benign pleural
effusion. Also, serum and pleural osteopontin are higher in
cases of mesothelioma than in benign pleural effusion. This re-
sult is concomitant with Bogdan-Dragos et al. [18] who de-
tected, that the serum osteopontin level was higher in MPM
patients compared with healthy asbestos exposed subjects
and a good capability of osteopontin to distinguish between
these two populations. They also revealed that serum mesoth-
elin had a good ability for diagnosing MPM but was unable to
identify patients with non epithelioid mesothelioma subtypes.Also Pass et al. [3] reported that osteopontin has been
proposed as an early marker for MPM diagnosis.
Creaney et al. [19] illustrated that most (>95%) patients
with mesothelioma have pleural effusion, it would be logical
to assess the usefulness of soluble mesothelin in the pleural
ﬂuid as a diagnostic test for mesothelioma. They also reported
that soluble mesothelin is detectable in pleural effusions and is
signiﬁcantly higher in pleural mesothelioma than in effusions
of benign pleuritis.
Harvey et al. [20] illustrated that osteopontin mediates cell
– matrix interactions and cell signaling through binding with
integrin and is regulated by proteins in cell – signaling path-
ways that are associated with asbestos – induced carcinogene-
sis. Moreover, high levels of osteopontin correlate with tumor
invasion, progression and metastases. So, osteopontin is a use-
ful biomarker in pleural mesothelioma.
Table 4 showed that both serum and pleural mesothelin are
higher in epitheliod type than in mixed or sarcomatoid type.
This result is concomitant with Daniel and Steven [14] who
reported that, soluble mesothelin is a useful marker for epithe-
liod mesothelioma but not for other histological variants of
mesothelioma. The result is concomitant with Bogdan-Dragos
et al. [18] who found that mesothelin had a good ability for
diagnosing MPM but was unable to identify patients with
non epithelioid mesothelioma subtypes.
This result can be explained by the fact that mesothelin is a
glycoprotein found predominantly in normal mesothelial cells
in pleura so, when MPM is formed the tumor burden increases
by an increase in the size of tumor and its secretions. Patients
with epithelial MPM and larger tumor had higher concentra-
tions of soluble mesothelin related peptides (SMRP) than
those with sarcomatoid histotype and smaller tumor size. Also,
a trend toward increasing SMRP concentrations with disease
progression was observed while SMRP levels fell after debul-
king surgery [21].
Table 5 showed that cases of mesothelioma with cutoff val-
ues of 4 nmol/L for pleural mesothelin and 3.4 nmol/L for ser-
um mesothelin, 370 ng/ml for pleural osteopontin and 350 ng/
ml for serum osteopontin or more had failed pleurodesis and
those with cutoff values less than these values had successful
pleurodesis.
This result can be explained by the fact that high levels of
these biomarkers indicate increased tumor burden that impairs
pleurodesis success. Siliva et al. [15] explained that cases with
low glucose and pH in the pleural ﬂuid traditionally have in-
creased tumor burden and decreased pleurodesis success.
Table 6 illustrates that pleural mesothelin shows higher sen-
sitivity than speciﬁcity (95.0% compared to 90.0%). On the
opposite side, pleural osteopontin shows higher speciﬁcity than
sensitivity (95.0% compared to 90.0%).
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protein attached to the cell surface; it is not a cancer-speciﬁc
antigen but a differentiation antigen thought to have a role
in cell adhesion and in cell-to-cell recognition and signaling.
It is over-expressed in several tumors such as mesothelioma,
pancreatic cancer and ovarian cancer [8], so it is a highly sen-
sitive but less speciﬁc marker. Pass et al. [3] investigated the
role of osteopontin in MPM, they found signiﬁcantly higher
speciﬁcity 85.5% than sensitivity 77.6%. This higher speciﬁcity
correlates with its role in tumor invasion, progression and
metastasis.Conclusion
The combined assays of blood and pleural ﬂuid mesothelin
and osteopontin biomarkers have a high diagnostic and prog-
nostic yield in malignant pleural mesothelioma patients under-
going pleurodesis.References
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